The MC38-OVAI-Ea cell adjuvant treatment of Bpmel tumor–bearing mice increased the count of tumor-infiltrating ARAFMUT-specific CD8+ T cells in the tumor (Fig. 1 H). This evidence concerns the gene CD8A and neoplasm.